Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

WHO says Congo’s Ebola outbreak is on track to eclipse the deadliest one in history

GENEVA (AP) — The ongoing Ebola outbreak in Congo is on track to eclipse the deadliest one in history that killed over 11,000 people…

The World Health Organization (WHO) predicts Congo's ongoing Ebola outbreak could surpass the deadliest one in history, which claimed over 11,000 lives from more than 28,000 cases in 2014 to 2016. Tedros Adhanom Ghebreyesus, the WHO director, stated that the current outbreak in eastern Congo, now in its third month, is moving faster than previous outbreaks and is considered the fastest-growing in history.

With over 2,000 deaths and more than 4,300 cases, the current outbreak is unlike most previous ones due to the rare Bundibugyo virus, which has no approved vaccines or treatments. The aggressive progression is attributed to the conflict-ridden region, with most new cases and fatalities occurring in hard-to-reach communities.

Written by urgent.news from Associated Press's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at apnews.com →

More in Health & Medicine

Celltrion ADC Candidates Win FDA Fast Track

All three antibody-drug conjugate (ADC)-based anticancer new drug candidates being developed by Celltrion have been named targets for the Fast Track designation by the U.S.

  • Celltrion secures FDA Fast Track designation for three ADC candidates.
  • CT-P73 targets recurrent and metastatic cervical cancer.
  • Designation aims to expedite development and commercialization.

Novo Nordisk FDA Setback Creates Opportunity for Korean CDMOs

Denmark’s Novo Nordisk, which has led the global pharmaceutical and biotech market on the back of explosive demand for the obesity treatments Wegovy and Ozempic, has run into an unexpected hurdle as…

  • FDA withholds approval for Novo Nordisk facilities due to quality-control violations.
  • Novo Nordisk's Bloomington facility received critical observations, including sterility failures.
  • Korean CDMOs like Celltrion and Samsung Biologics benefit from regulatory challenges.